Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $299

AbbVie, Inc. -0.96%

AbbVie, Inc.

ABBV

230.11

-0.96%

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE: ABBV) with a Overweight and raises the price target from $289 to $299.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via